Lumexa Imaging Reports Strong Q4 & FY25 Adjusted EBITDA Growth, Slashes Leverage by Two Turns
LMRI is trading near its 52-week low of $9.965 (11% above the low) on elevated volume (1.8× avg).
Summary
Lumexa Imaging announced robust fourth quarter and full year 2025 financial results, showcasing significant operational improvements and a strengthened balance sheet. For Q4 2025, consolidated revenues increased 7.9% to $267.7 million, with Adjusted EBITDA rising 18.6% to $63.8 million. Full year 2025 saw revenues grow 7.8% to $1.023 billion and Adjusted EBITDA increase 14.6% to $230.2 million. Critically, the company achieved a two-turn reduction in leverage, moving from 5.5 times to 3.5 times, which is expected to generate over $50 million in annual cash savings. The company also reiterated its full year 2026 guidance, projecting continued growth. This strong performance, particularly the material deleveraging, significantly improves the company's financial health and reduces risk, providing a solid foundation for future growth initiatives.
At the time of this announcement, LMRI was trading at $11.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1B. The 52-week trading range was $9.97 to $19.45. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.